Skip to main content

Cellular Dynamics Prices IPO

NEW YORK (GenomeWeb News) – Cellular Dynamics International has priced its initial public offering at $12 per share, the stem cell technology firm announced late Wednesday.

Its shares are anticipated to trade on the Nasdaq under ticker symbol "ICEL." CDI is offering about 3.8 million shares in its IPO. Additionally it granted its underwriters a 30-day option to purchase an additional 576,900 shares.

JP Morgan Securities is the sole book-running manager on the offering. Cowen &Co and Leerking Swann are co-managers.

Proceeds will go toward R&D, sales and marketing, expansion of its sales force for commercialization of its products, building out of its laboratory, and working capital general corporate purposes.

CDI filed for its IPO last month.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.